Sickle Cell Disease Scd clinical trials

Explore recruiting sickle cell disease scd clinical trials.

Recruiting sickle cell disease scd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sickle Cell Disease Scd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease

Spain, France, Netherlands, Belgium, Greece, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy

France, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.

Netherlands, Germany, Belgium, France, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

Belgium, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease

Germany, France, Italy, Spain, Greece

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

Belgium, Netherlands, France, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

Sickle Cell Disease Scd trials by city

Sickle Cell Disease Scd in Toronto Sickle Cell Disease Scd in Vancouver Sickle Cell Disease Scd in Montreal Sickle Cell Disease Scd in Calgary Sickle Cell Disease Scd in Edmonton Sickle Cell Disease Scd in Ottawa Sickle Cell Disease Scd in Winnipeg Sickle Cell Disease Scd in Quebec City Sickle Cell Disease Scd in Hamilton Sickle Cell Disease Scd in Kitchener Sickle Cell Disease Scd in London Sickle Cell Disease Scd in Halifax Sickle Cell Disease Scd in New York Sickle Cell Disease Scd in Los Angeles Sickle Cell Disease Scd in Chicago Sickle Cell Disease Scd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease